Serum-based protein biomarkers in blast-induced traumatic brain injury spectrum disorder

Denes V. Agoston1,2,* and Mohammad Elsayed1,3

1 Department of Anatomy, Physiology and Genetics, Uniformed Services University, Bethesda, MD, USA
2 Experimental Trauma Unit, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
3 Veterans Affairs Central Office, U.S. Department of Veterans Affairs, Washington, DC, USA

The biological consequences of exposure to explosive blast are extremely complex. Serum protein biomarkers in blast-induced traumatic brain injury (bTBI) can aid in determining injury severity, monitoring progress, and predicting outcome. Exposure to blast results in varying degrees of physical injury. Explosive blast can also induce psychological stress that can contribute to or amplify the extent of physical damage. Given the complexity, scale of injury, and variety of symptoms, bTBI may be best described as a spectrum disorder. In this focused review, we summarize the status of serum protein biomarkers in bTBI in the context of the classification and pathological changes of other forms of TBI. Finally, we recommend specific and easily implementable measures to accelerate serum protein biomarker discovery and validation in bTBI.

Keywords: blood, proteomics, traumatic, brain, injury, blast, biomarkers, serum

Serum protein biomarkers have long held promise in the treatment of traumatic brain injury (TBI). They can aid in diagnosing the disease, monitoring progress, predicting outcome, and providing pertinent molecular information about ongoing pathological changes for designing evidence-based therapeutic interventions (Kochanek et al., 2011). Serum protein biomarkers are of special importance in blast-induced TBI (bTBI) because they are typically associated with military operations with limited access to imaging and other diagnostic tools of hospitals (Agoston et al., 2009).

The physical and biological consequences of explosive blast are extremely complex. Blast generates high energy supersonic pressure waves, heat, toxic gases, electromagnetic pulses, etc. (Champion et al., 2009; Ramasamy et al., 2009a,b; Hicks et al., 2010; Nakagawa et al., 2011). How each of these forces, separately or in a combinatorial fashion interact with the brain and body is still poorly understood. While the cause of bTBI is exposure to blast, injury severity may range from mild to severe and result in outcomes that cover a wide set of symptoms (Mayorga, 1997; Guy et al., 2000; Elder and Cristian, 2009; Elder et al., 2010; Rosenfeld and Ford, 2010; Marion et al., 2011). Exposure to blast can also cause severe psychological stress that can contribute to or amplify the extent of physical damage (Kluger et al., 2004; Ling et al., 2009; Wallace, 2009; Wolf et al., 2009; Ling and Ecklund, 2011).

Accordingly, bTBI may be best described as a spectrum disorder. Similar to other forms of TBI, the classification of bTBI is currently based on subjective neurobehavioral evaluations including the Glasgow Coma Scale (GCS) and the Military Acute Concussion Evaluation (MACE; Cernak et al., 1999; Secer et al., 2007; Bochicchio et al., 2008; Peleg and Savitsky, 2009; Rosenfeld and Ford, 2010; Tarmey et al., 2011). These functional assessments are only occasionally supplemented with information from neuroimaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI; Ling and Ecklund, 2011).

In this paper, we provide a brief overview of the status of serum protein biomarkers in bTBI. Because of the limited information about protein biomarkers specific to blast injury, we will discuss them in the context of the classification and pathological changes of other forms of TBI.

EPIDEMIOLOGY OF TBI AND bTBI

Traumatic brain injury is an enormous public health concern. The Centers for Disease Control and Prevention (CDC) estimates that ~1.7 million Americans sustain TBI every year (Coronado et al., 2011). TBI also contributes to about a third of all injury-related deaths, resulting in over 52,000 deaths a year (Coronado et al., 2011).

Improving TBI treatment for military personnel is especially pressing. The incidence of TBI for armed forces, even during peacetime, is greater than civilian populations (Ommaya et al., 1996). Also, due in part to the nature of modern combat, the
incidence rates of TBI have been increasing since 2000 (Sayer, 2012). Although it is difficult to assess exactly how many soldiers are victims of TBI (especially because many are not properly diagnosed), estimates from Veterans Affairs medical records report that about 7% of veterans from Iraq and Afghanistan received a TBI diagnosis (Taylor et al., 2012). Other survey studies suggest that 11–23% of military personnel deployed to Iraq or Afghanistan may have sustained at least mild TBI (Sayer, 2012). Studies from the Rand Corporation estimate that about of fifth of returning members suffer from TBI (Tenielian and Jaycox, 2008).

Blast injury from improvised explosive devices (IEDs) is an especially common form of TBI among military populations. According to the Joint Theater Trauma Registry, IEDs were the source of about 80% of all casualties from Iraq and Afghanistan between October 2001 and January 2005 (Owens et al., 2008). In another review of US Army casualties in Afghanistan and Iraq between 2001 and 2007, explosions were linked with 63% of all TBI diagnoses (Wojcik et al., 2010). Another similar survey of US Navy and Marine casualties in Iraq in 2004 found that 52% of all TBI cases involved explosions (Galarneau et al., 2008). Despite the variability of these studies, it is evident that TBI and bTBI especially affects a great deal of soldiers, thus requiring the need for improved diagnostics and treatments.

**CLASSIFICATION OF BLAST-INDUCED TRAUMATIC BRAIN INJURY**

Individuals who experience less than 30 minutes of lost or altered levels of consciousness after exposure to blast are classified as having suffered mild bTBI (mibTBI; Figure 1; Trudeau et al., 1998; Hoge et al., 2008; Elder et al., 2010; Levin et al., 2010; Rosenfeld and Ford, 2010; Wilk et al., 2010). This initial period may be followed by post-injury amnesia that lasts no longer than 24 hours. There are typically no penetrating injuries to the head or other organs, and neurological deficits (if any) are focal and transient in nature. Concurrently, the GCS score is nearly perfect at 13–15. The transient and mild neuropsychiatric deficits are typically followed by full recovery. However, similar to other types of mild TBI, a delayed onset of functional changes and long-term disabilities may still occur, especially after multiple exposures to mild blasts (Stern et al., 2011). Importantly, mibTBI shares symptoms and is often comorbid with post-traumatic stress disorder (PTSD; Hoge et al., 2008; Levin et al., 2010; Rosenfeld and Ford, 2010; Ursano et al., 2010). The combination of physical damage and psychological effects makes mibTBI especially difficult to diagnose. Thus, serum protein biomarkers that can distinguish between the physical and psychological components of the injury would be of special value (see also Figures 2 and 3 and discussion below).

Blast-induced traumatic brain injury is classified as moderate if loss of consciousness is longer than 30 minutes, post-injury amnesia lasts longer than 24 hours, and the initial GCS score is between 9 and 12 (Figure 1; Thompson et al., 2008; Aarabi and Simard, 2009; Wolf et al., 2009; Drake et al., 2010). The long-term outcome of moderate bTBI (mobTBI) can include detectable and significant levels of cognitive and neuropsychiatric abnormalities. Moderate bTBI can also be comorbid with PTSD and injuries to other organs.

According to the current classification system, bTBI is severe if the GCS score is less than 9 (Figure 1; Ling and Marshall, 2008; Ling et al., 2009; Ling and Ecklund, 2011). In the severe form of bTBI (sbTBI), polytrauma, i.e., injuries to other parts of the body, most frequently to the extremities, abdomen, and lungs can significantly contribute to and modify the pathology and outcome of brain injury. In addition to its comorbidity with polytrauma, sbTBI is often the result of multiple types of brain injury. Beyond the damage caused by the primary components of blast, various objects, debris, and shrapnel may break through the
The initial interactions between the physical forces of blast and the brain trigger pathological responses called the primary injury process or mechanism. The pathological components of the primary injury mechanism are largely influenced by whether the blast is experimental (bTBI Experimental) or clinical (bTBI Clinical). The pathological mechanisms and associated serum protein biomarkers in blast TBI can be illustrated as follows:

### Pathological Mechanisms and Associated Serum Protein Biomarkers in bTBI

The pathological mechanisms and associated serum protein biomarkers in blast TBI are primarily involved in the protection response, apoptosis, and the inflammatory response. These mechanisms can be further categorized into biological, cellular, and extracellular processes, each with specific serum protein biomarkers. The table below summarizes the biomarkers associated with these mechanisms:

### Table: Pathological Mechanisms and Associated Serum Protein Biomarkers in bTBI

| Biomarker   | Cell Specificity | Function | bTBI Experimental | bTBI Clinical | TBI Experimental | TBI Clinical |
|-------------|-----------------|----------|-------------------|---------------|-----------------|-------------|
| HIF-1α      | Ubiquitous      | Nucleus, cytoplasm | Induced by hypoxia, activates cell protection response | Yes | Yes | 25, 26 |
| Secretagogin | Ubiquitous      | Nucleus, cytosol  | Ca2+ binding protein | Yes | Yes | 11 |
| IL-1β       | Glia, immune cells | Serum, cell receptors | Released as part of inflammatory response | Yes | Yes | 11, 12 |
| IL-6        | Glia, immune cells | Serum, cell receptors | Released as part of inflammatory response | Yes | Yes | 11, 12 |
| IL-8        | Glia, immune cells | Serum, cell receptors | Released as part of inflammatory response | Yes | Yes | 11, 12 |
| TNF-α       | Activated macrophages | Serum, cell receptors | Released as part of inflammatory response, apoptosis | Yes | Yes | 6, 11, 12 |
| UCH-L1      | Neurons, neuroendocrine tissue | Cytoplasm  | Ubiquitin hydrolisis | Yes | Yes | 3, 4, 23 |
| C-tau       | Neurons, low level in astrocytes and oligodendrocytes | Microtubules  | Axoplasmic flow, microtubule formation | Yes | Yes | 3, 4, 23 |
| Alpha II -Spectrin | Neurons, axon | Cytoplasm | Structural component of neuronal axonal cytoskeleton | Yes | Yes | 3, 4, 23 |
| SBPs        | Neuron, axon  | Serum  | Cleaved by calpain - and caspase - derived proteases | Yes | Yes | 3, 4, 23 |
| Ceruloplasmin | Ubiquitous | Serum | Copper -carrier protein involved in copper and iron metabolism | Yes | Yes | 3, 4, 23 |
| vWF         | Mainly endothelial cells, other cell types | Serum, cell receptors | Glycoprotein involved in hemostasis | Yes | Yes | 3, 4, 23 |
| VEGF        | Ubiquitous | Serum, cell receptors | Promotes angiogenesis | Yes | Yes | 3, 4, 23 |
| Claudin-5   | Mainly endothelial cells | Cell membrane, tight junctions | Involved in forming tight junctions, regulating paracellular transport | Yes | Yes | 3, 4, 23 |
| AQP4        | Mainly astrocytes | Cell membrane | Water channel | Yes | Yes | 3, 4, 23 |
| MMP9        | Ubiquitous | Extracellular matrix | Involved in breaking down extracellular matrix | Yes | Yes | 3, 4, 23 |
| HIF-1α      | Ubiquitous | Nucleus, Cytoplasm | Induced by hypoxia, activates cell protection response | Yes | Yes | 3, 4, 23 |

The table above illustrates the biological, cellular, and extracellular processes involved in the pathological mechanisms of blast TBI. The serum protein biomarkers associated with these mechanisms are critical for monitoring the injury severity and response to treatment. Further research is needed to validate these biomarkers and their clinical relevance in blast TBI.

### References

- Anderson et al. (2008), Sirvan et al. (2009), Sandler et al. (2010), da Rocha et al. (2005), Akinoshita et al. (2002), Stein et al. (2011).
- Hayakata et al. (2004), Subotovic et al. (2007), Sarraf et al. (2004), Liu et al. (2010), Berger et al. (2012), Pappa et al. (2010), Zeman et al. (2002), Gabbara et al. (2008), Butuk et al. (2006), Pike et al. (2001), Nevsecomb et al. (1997), Ringer et al. (2004), Saatman et al. (2010), Dash et al. (2010), Young et al. (1988), De Oliveira et al. (2007), Ahmed et al. (in preparation), Higashida et al. (2011), Garman et al. (2011), Zurek et al. (2011), Brophy et al. (2009).
**Events** | **Mechanism** | **Candidate Serum Biomarkers**
--- | --- | ---
**Neuronal and Glial Cell Death** | Activation of factors triggering necrosis and/or apoptosis | Neuronal: NSE, C-tau, SBP, All-Spectrin
Glial: S100β, GFAP, MBP, C-tau

**Vasospasm** | Dysregulation of vascular constriction and relaxation | -
Hsp70, TNF-α, VEGF, Claudin-5, vWF

**Edema** | Vasogenic and cytotoxic events caused by toxic and inflammatory factors | -
Hsp70, IL-β, IL-β, IL-8, VEGF, Claudin-5, vWF, AQP4, MMP9

**Axonal Injury** | Mechanical injury; Neuronal degeneration | S100β, NSE, C-tau, MBP, SBP, All-Spectrin
S100β, MBP, NSE, PNF-H, NMDAR, Hsp70, C-tau, All-spectrin, SBP
S100β, MBP, NSE, PNF-H, NMDAR, Hsp70, C-tau, All-spectrin, SBP

**Inflammation** | Cytokine release and cellular stress | IL-1β, IL-1β, IL-8, TNF-α, IFN-γ
Hsp70, IL-β, IL-β, IL-8, TNF-α, IFN-γ
Hsp70, IL-β, IL-β, IL-8, TNF-α, IFN-γ

**Metabolic Changes** | Hypoxia; altered energy demand, ion homeostasis and neurotransmission; increased repair processes | -
Ceruloplasmin, HIF-1α
Ceruloplasmin, HIF-1α

| **Mild TBI** | **Moderate TBI** | **Severe TBI** |
--- | --- | ---
Neuronal: NSE, pNF-H, NF-H, NMDAR, Hsp70, UCH-L1, C-tau, All-spectrin, SBP, Secretagogin | Neuronal: NSE, pNF-H, NF-H, NMDAR, Hsp70, UCH-L1, C-tau, All-spectrin, SBP, Secretagogin | Neuronal: NSE, pNF-H, NF-H, NMDAR, Hsp70, UCH-L1, C-tau, All-spectrin, SBP, Secretagogin

**FIGURE 3** | Candidate serum protein biomarkers associated with injury severity and selected pathological mechanisms.

called the secondary injury mechanism. These pathologies include metabolic changes, neuroinflammation, axonal injury, vascular abnormalities, and neuronal and glial cell death (Ghirnikar et al., 1998; Lenzlinger et al., 2001; Vink et al., 2001; Morganti-Kossmann et al., 2002; Nortje and Menon, 2004; Warden et al., 2006; Cernak and Noble-Hausslein, 2010; Donkin and Vink, 2010). Metabolic changes include abnormal levels of oxygenation (hypoxia), altered cell metabolism (e.g., glucose utilization), disrupted energy levels and utilization (leading to ionic imbalance, excitotoxicity, etc.), systemic hormonal secretion, and an upregulation of inflammatory activity (Cook et al., 2008; Feng et al., 2012). Inflammation is almost always a result of injury, and occurs in response to damaging stimuli, triggering the release and activation of cytokines and chemokines and the activation and proliferation of microglia (and astroglia) in the CNS. A propagating immune response may promote neurotoxicity and vascular changes (Morganti-Kossmann et al., 2007; Ziebell and Morganti-Kossmann, 2010; Brown et al., 2011). Vascular abnormalities are marked by aberrations in the water content of the brain parenchyma, dysregulation of water channels, and a compromised blood-brain barrier (BBB). Vascular abnormalities can be triggered by cyto- and vasogenic factors leading to edema, vasospasm, and altered rates of perfusion. Diffuse axonal injury is also common, and entails a loss of membrane integrity, altered axonal architecture, Wallerian-type axonal degeneration, metabolic disruption leading to degeneration, and increased serum levels of axonal proteins and filaments (Meythal et al., 2001). Finally, neuronal and glial cell loss results from necrotic and apoptotic cell death during primary and secondary injury, and may lead to an increase in various neuron- and glia-specific proteins in serum (Stoica and Faden, 2010). Compounded together, these primary and secondary injury processes may lead to a range of neuropsychiatric symptoms, including various forms of memory and learning deficits, anxiety, and depression (Arciniegas, 2011).

According to our current understanding, the various forms of TBI can share common pathological “components” during both the primary and the secondary injury processes. What likely distinguishes the various forms of TBIs are the onsets and relative contributions of these individual components to the overall pathological cascades. Earlier works in different forms of TBI have identified candidate biomarkers associated with the various pathological changes (Figures 2 and 3). Many of these markers are neuron- and glia-specific and reflect damage to the different cellular components of the brain. Others are more ubiquitous and may indicate generalized metabolic changes, inflammation, etc. Changes in the serum levels of some of these markers have also been found in bTBI. The onset, intensity, and temporal patterns of the various pathological components likely depend on the severity of the injury (Figure 4). For example, one of the distinguishing features of sbTBI is the unusually early onset (within hours after exposure) and extent (high severity) of edema, whereas vasospasm is unusually delayed (up to 2 weeks post-injury; Ling and Marshall, 2008; Ling et al., 2009; Ling and Ecklund, 2011). It should also be noted that hemorrhage is not associated with mibTBI, but is highly characteristic of sbTBI (Ling and Marshall, 2008; Ling et al., 2009; Ling and Ecklund, 2011).

The temporal aspects of injury, like the onset of the various pathologies, are especially important in dynamically changing diseases like bTBI. An experimental study investigating the temporal patterns of the various pathological components likely depend on the severity of the injury (Figure 4). For example, one of the distinguishing features of sbTBI is the unusually early onset (within hours after exposure) and extent (high severity) of edema, whereas vasospasm is unusually delayed (up to 2 weeks post-injury; Ling and Marshall, 2008; Ling et al., 2009; Ling and Ecklund, 2011). It should also be noted that hemorrhage is not associated with mibTBI, but is highly characteristic of sbTBI (Ling and Marshall, 2008; Ling et al., 2009; Ling and Ecklund, 2011).

The temporal aspects of injury, like the onset of the various pathologies, are especially important in dynamically changing diseases like bTBI. An experimental study investigating the temporal
pattern of changes in serum levels of four of the most commonly used clinical and experimental biomarkers, S100β, NSE, MBP, and NF-H showed that the temporal pattern of changes can reflect injury severity. Using a swine model of explosive blast and monitoring changes in the serum levels of the four markers up to 2 weeks post-injury, Gyorgy et al. (2011) found increases over time in the serum levels of all four markers. Importantly, the temporal pattern of changes in the serum levels of NF-H showed that in sbTBI, serum NF-H levels peaked early (within 6 hours after injury). The temporal pattern of changes of the other three markers showed no correlation with injury severity. This study illustrates how monitoring the temporal pattern of changes (e.g., “time to peak”) of serum biomarkers can be useful for identifying injury severity and outcome. This study also underlines the importance of monitoring changes in serum levels of several markers as they can reflect the dynamics of distinct but important pathologies, e.g., glial response (GFAP and S100β) vs. axonal damage (NF-H).

Experimental data derived from a rodent model of bTBI has shown that in addition to neuronal and glial cell damage, there are also vascular abnormalities that occur in mibTBI (Kovesdi et al., 2011; Kwon et al., 2011). Elevated serum levels of neuron- or glia-specific proteins (NF-H, NSE, CK-BB; GFAP, MBP, S100β) indicate increased permeability of the BBB (in addition to neuronal and glial cell damage or loss). In the same study, the authors found more direct evidence of vascular abnormalities. Serum levels of VEGF, a protein associated with regulating complex vascular functions including vascular permeability (Neufeld et al., 1999; Croll et al., 2004; Rosenstein and Krum, 2004), were significantly elevated. This study has the limitation of measuring serum levels of the protein markers only at a single, terminal time point.
However, the terminal time point of the elevated serum protein markers was taken more than 2 months after injury. This finding indicates that there may be long-lasting ongoing pathological changes, even after a single exposure to mild blast. These findings can have great clinical relevance if they can be repeated. Given the large number of soldiers exposed to a single mild blast, and our very limited knowledge about the long-term consequences of blast, a longitudinal study focusing on a few protein biomarkers should be considered. The data from such a study can be correlated with long-term neurobehavioral assessments in order to identify individuals with increased vulnerabilities and also result in a better understanding of the pathobiology of mTBI.

In addition to neuronal and glial damage, there is also experimental evidence of neuroinflammation and vascular changes as pathological responses to bTBI (Agoston et al., 2009; Kamnaksh et al., 2011; Kovesdi et al., 2011; Kwon et al., 2011). Along with elevated serum levels of VEGF, there is data showing increased levels of Claudin-5 and vWF in rodents after repeated exposures to mild blasts (Ahmed et al., in preparation). The temporal pattern of changes in their serum levels and the correlation between injury severity and the temporal patterns are currently being investigated (Ahmed et al., in preparation).

Evidence from the study discussed above also showed that animals that were exposed to stressful conditions (in order to simulate battlefield conditions and trigger PTSD) but were not injured had no increase in the serum levels of the previously mentioned protein biomarkers (Kwon et al., 2011). Despite this, they had increased serum corticosterone (CORT) levels and displayed behavioral pathologies like increased anxiety. These findings indicate that one may be able to design objective, serum-based differential diagnostics to distinguish between mTBI and PTSD. Such a test would be especially important because mTBI is the most frequent form of blast-induced neurotrauma, accounting for approximately 70% of all bTBIs (Trudeau et al., 1998; Thompson et al., 2008; Elder and Cristian, 2009; Elder et al., 2010; Rosenfeld and Ford, 2010). Moreover, PTSD has emerged as one of the most frequent and lasting consequences of recent military conflicts (Rosenfeld and Ford, 2010; Belanger et al., 2011; Luethcke et al., 2011). Mild bTBI and PTSD have overlapping neurobehavioral symptoms, clinically as well as experimentally. Based on current knowledge, exposure to blast can trigger cellular damage, thus requiring different therapeutic interventions than those used for PTSD (Thompson et al., 2008; Elder et al., 2010; Luethcke et al., 2011). Soldiers showing no functional deficit based on current neurobehavioral assessments (e.g., MACE) after exposure to mild levels of explosive blast return to duty and often become re-exposed to additional blasts (Hayes et al., 2012). As early studies implicate, additional exposures can have severe consequences, including an increased risk of developing long-term neuropsychiatric abnormalities (Okie, 2005; Peota, 2005; Aarabi and Simard, 2009; Jaffe and Meyer, 2009; Cernak et al., 2011; Plurad, 2011; Hayes et al., 2012). Serum protein biomarkers that can indicate the extent of individual vulnerability are of major value. For example, advanced “bio-dosimeters” can be developed for soldiers by using a combination of serum-based health information and physical parameters provided by helmet-mounted sensors (accelerometers). Such a personalized tool can indicate the real-time vulnerability of a soldier to any additional blast. Similar personalized “dosimeters” can also be developed for athletes with a high risk of repeated TBI, such as NFL players.

There are several conceptual, logistical, and technical problems associated with developing serum biomarkers as a diagnostic tool in neuronal insults like TBI. Technical problems include selecting the best proteomics method for serum biomarker discovery (Agoston et al., 2009). To facilitate the antibody-based validation of serum protein biomarkers in bTBI, we listed potential markers as a function of their association with different pathologies and severities of TBI (Figure 3). Some of the markers (“the usual suspects”) have been well studied, established, and analyzed in bTBI (Bauman et al., 2009; Gyorgy et al., 2011; Kovesdi et al., 2011; Kwon et al., 2011). Unfortunately, only a few of the listed markers have been verified by clinical studies to show changes in their serum levels specifically due to injury to the brain (and not to other organs). Even fewer markers have been evaluated in clinical settings and correlated with functional and neurobehavioral changes (e.g., GCS and other neurobehavioral tests) routinely used in clinical settings (Agoston et al., 2012).

In addition to aiding in the diagnosis and assessment of injury severity, serum protein biomarkers in mTBI can provide critical information for designing individualized treatment and for monitoring disease progression and treatment effectiveness. Simple versions of such an approach are already in use at neurointensive care units, where serum C-reactive Protein levels are monitored to assess general inflammation and treatment effectiveness. However, the current lack of clinical evidence about how changes in serum levels of protein biomarkers correlate to pathomechanisms and functional outcomes in TBI is a major hindrance. Concentrated, large scale, and preferably international research efforts are needed in order to generate reliable and clinically useful information for aiding in the evidence-based treatment of TBI.

**SUMMARY AND FUTURE DIRECTIONS**

We would like to conclude this focused review by suggesting three relatively easy and implementable measures that can speed up both serum protein biomarker discovery and validation in bTBI. First: blood should be obtained at multiple time points (serial sampling) in both experimental and clinical studies in order to enable the longitudinal analysis of changes in serum levels of protein markers in bTBI. This approach can reveal temporal patterns of changes that may be of vital diagnostic and therapeutic value. Second: changes in the serum levels of a whole panel of proteins rather than a single protein need to be analyzed (at multiple time points). Multiplex assays, already in use in cancer biology, can provide substantially improved diagnostic precision, and especially so if combined with a systems biology analysis. Third: changes in serum protein biomarkers should be analyzed in relation to functional and neurobehavioral changes in both clinical and experimental settings. Such a combined analysis would radically improve the diagnostic and prognostic value of serum protein biomarkers by facilitating a much more direct understanding of how serum changes relate to functional deficits.

In addition to proteins, there are other potential biomarkers such as microRNAs. While microRNAs have some advantages (e.g.,
Evidence-based treatments for individuals suffering from the consequences of blast injury.

ACKNOWLEDGMENTS

We thank Dr. Farid Ahmed and Ms. Alaa Kamnaksh for their discussion and editorial assistance. Mohammad Elsayed was supported by Denes V. Agoston grant # B5044R.
A novel multicenter preclinical drug screening and biomarker consortium for experimental traumatic brain injury: operation brain trauma therapy. J. Trauma 71, S15–S24.

Kovesdi, E., Gyorgy, A. B., Kwon, S. K., Wingo, D. L., Kamnaksh, A., Long, J. B., Kaper, C. E., andagos, T. D. (2011). The effect of enriched environment on the outcome of traumatic brain injury: a behavioral, proteomics, and histological study. Front. Neurosci. 5:42. doi:10.3389/fnins.2011.00042

Kwon, S. K., Kovesdi, E., Gyorgy, A. B., Wingo, D., Kamnaksh, A., Walker, J., Long, J. B., and Agoston, D. V. (2011). Stress and traumatic brain injury: a behavioral, proteomics, and histological study. Front. Neurol. 2:12. doi:10.3389/neurol.2011.00012

Lenzlinger, P. F., Morganti-Kossmann, M. C., Laurer, H. L., and McIntosh, T. K. (2001). The duality of the inflammatory response to traumatic brain injury. Mol. Neurobiol. 24, 169–181.

Levin, H. S., Wilde, E., Troyanskaya, M., Petersen, N. J., Scheibel, R., Newsome, M., Radaideh, M., Wu, T., Yallampalli, R., Chu, Z., and Li, X. (2010). Diffusion tensor imaging of mild to moderate blast-related traumatic brain injury and its sequelae. J. Neurotrauma 27, 683–694.

Ling, G., Bandak, F., Armonda, R., Grant, G., and Ecklund, J. (2009). Explosive blast neurotrauma. J. Neurol. Neurosurg. Psychiatry 80, 815–825.

Ling, G. S., and Ecklund, J. (2011). Traumatic brain injury in modern war. Curr. Opin. Anaesthesiol. 24, 124–130.

Ling, G. S., and Marshall, S. A. (2008). Management of traumatic brain injury in the intensive care unit. Neurocrit. Care 26, 409–426 viii.

Liu, M. C., Akiyori, L., Scharf, D. M., J. L., Narner, S., Muller, U., Oli, M. W., Zheng, W., Kobeissy, F. Papa, L., Xu, X. C., Dave, J. R., Tortella, F. C., Hayes, R. L., and Wang, K. K. (2010). Ubiquitin C-terminal hydrolyase-11 as a biomarker for ischemic and traumatic brain injury in rats. Eur. J. Neurosci. 31, 722–732.

Liu, M. C., Aike, V., Zheng, W., Kitlen, J., O’Sheen, B., Lartey, N., Dave, J. R., Tortella, F. C., Hayes, R. L., and Wang, K. K. (2006). Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury. J. Neurochem. 98, 700–712.

Luethke, C. A., Bryan, C. I., Morrow, C. E., and Isler, W. C. (2011). Comparison of concussive symptoms, cognitive performance, and psychological symptoms between acute blast-versus nonblast-on blast-induced mild traumatic brain injury. J. Int. Neuropsychol. Soc. 17, 36–45.

Marion, D. W., Curely, K. C., Schwab, K., and Hicks, R. R. (2011). Proceedings of the military mTBI Diagnostics Workshop. St. Pete Beach, August 2010. J. Neurotrauma 28, 517–526.

Mayorga, M. A. (1997). The pathology of primary blast overpressure injury. Toxicology 121, 17–28.

Meythaler, J. M., Peduzzi, J. D., Eleffferio, E., and Novack, T. A. (2001). Current concepts: diffuse axonal injury-associated traumatic brain injury. Arch. Phys. Med. Rehabil. 82, 1461–1471.

Morganti-Kossmann, M. C., Rancan, M., Stahel, F. E., and Kossman, T. (2002). Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr. Opin. Crit. Care 8, 101–105.

Morganti-Kossmann, M. C., Satguriaselvan, L., Byne, N., and Kossman, T. (2007). Modulation of immune response by head injury. Injury 38, 1392–1400.

Nakagawa, A., Manley, G. T., Gean, A. D., Ohtani, K., Armonda, R., Tsukamoto, A., Yamamoto, H., Takayama, K., and Tominaga, T. (2011). Mechanisms of primary blast-induced traumatic brain injury: insights from shock-wave research. J. Neurotrauma 28, 1101–1119.

Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASER J 3, 9–22.

Newcomb, J. C., Kampf, A., Posman- tar, R. M., Zhao, X., Pike, B. R., Liu, S. J, Clifton, G. L, and Hayes, R. L. (1997). Immunohistoche- mical study of calpain-mediated broken-down products to alpha-spectrin following controlled cortical impact injury in the rat. J. Neurotrauma 14, 369–383.

Nortje, J., and Menon, D. K. (2004). Traumatic brain injury: physiology, mechanisms, and outcome. Curr. Opin. Neurol. 17, 711–718.

O’Sheen, B. S. (2005). Traumatic brain injury in the war zone. N. Engl. J. Med. 352, 2043–2047.

Ommaya, A. K., Dannenberg, A. L., and Salazar, A. M. (1996). Causa- tion, incidence, and costs of traumatic brain injury in the U.S.
Agoston and Elsayed

Serum biomarkers in blast TBI

July 2012 | Volume 3 | Article 107 | 9

military medical system. J. Trauma 40, 211–217.

Owens, B. D., Kragh, J. E. Jr., Wenke, J. C., Macaitis, J., Wade, C. E., and Holcomb, J. B. (2008). Combat wounds in operation Iraqi Freedom and operation Enduring Freedom. J. Trauma 64, 295–299.

Papa, L., Akinyn, L., Liu, M. C., Pineda, J. A., Tepas, J. I. 3rd, Olii, M. W., Zheng, W., Robinson, G., Robicsek, S. A., Gabrielli, A., Heaton, S. C., Hannay, H. J., Demery, J. A., Brophy, G. M., Layon, J., Robertson, C. S., Hayes, R. L., and Wang, K. K. (2010). Uzbekistan C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit. Care Med. 38, 138–144.

Papa, L., Lewis, L. M., Falk, J. L., Zhang, Z., Silvestri, S., Giordano, P., Brophy, G. M., Demery, J. A., Dixit, N. K., Ferguson, L., Liu, M. C., Mo, J., Akinyn, L., Schmid, K., Mondello, S., Robertson, C. S., Tortella, F. C., Hayes, R. L., and Wang, K. K. (2012). Elevated levels of serum gial fibrillary acidic protein breakdown products in mild and moderate trauma brain injury are associated with intracranial lesions and neurosurgical intervention. Ann. Emerg. Med. 59, 471–483.

Peleg, K., and Savitsky, B. (2009). Terrorism-related injuries versus road traffic accident-related trauma: 5 years of experience in Israel. Disaster Med. Public Health Prep 3, 196–200.

Pelinka, L. E., Kropael, A., Leinser- ing, M., Buchinger, W., Raabe, A., and Redl, H. (2004). GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J. Neurotrauma 21, 1553–1561.

Peota, C. (2005). Invisible wounds. Minn. Med. 88, 13–14.

Petzold, A. (2005). Neurofilament phosphophosphate: surrogate markers for axonal injury, degeneration and loss. J. Neural Sci. 233, 183–198.

Pike, B. R., Flint, J., Dutta, S., Johnson, E., Wang, K. K., and Hayes, R. L. (2001). Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J. Neurochem. 78, 1297–1306.

Pina, J. A., Wang, K. K., and Hayes, R. L. (2004). Biomarkers of proteolytic damage following traumatic brain injury. Brain Pathol. 14, 202–209.

Pleines, U. E., Moriggi-Kossman, M. C., Rancan, M., Joller, H., Trenta, O., and Kossman, T. (2001). S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J. Neurotrauma 18, 491–498.

Plurad, D. S. (2011). Blast injury. Mil. Med. 176, 276–282.

Ramasamy, A., Hill, A. M., and Clasper, J. C. (2009a). Improvised explosive devices: pathophysiology, injury profiles and current medical management. J. R. Army Med. Corps. 155, 265–272.

Ramasamy, A., Hill, A. M., Hepper, A. E., Bull, A. M., and Clasper, J. C. (2009b). Blast blast: mines; physics, injury mechanisms and vehicle protection. J. R. Army Med. Corps. 155, 258–264.

Ringger, N. C., O’Steen, B. E., Brabham, J. G., Silver, X., Pineda, J., Wang, K. K., Hayes, R. L., and Papa, L. (2004). A novel marker for traumatic brain injury: CSF alpha-spectrin breakdown product levels. J. Neurotrauma 21, 1443–1456.

Rosenfeld, J. V., and Ford, N. L. (2009). Head injuries due to landmine explosion of injury severity and brain temperature. Neurosurgery 55, 416–424; discussion 424–415.

Sawyer, N. A. (2012). New roles for VEGF in nervous tissue – beyond blood vessels. Exp. Neurol. 187, 246–253.

Rotheroe, R. D., Brawanski, A., and Woertgen, C. (2000). S-100B protein serum levels after controlled cortical impact injury in the rat. Acta Neurochir. (Wien) 142, 199–203.

Saatman, K. E., Creed, J., and Raghu- man, G. M., Demery, J. A., Dixit, N. D., Gutierrez, H., Curley, K. C., Hayes, R. L., and Wang, K. K. (2010). Morphologic and biochemical characterization of brain injury in a model of controlled blast overpressure exposure. J. Trauma 69, 785–794.

Tarmy, N. N., Park, C. L., Bartels, O. J., Konig, T. C., Mahoney, P. F., and Mellor, A. J. (2011). Outcomes following military traumatic cardiopulmonary arrest: a prospective observational study. Resuscitation 82, 1194–1197.

Taylor, B. C., Hagel, E. M., Carlson, K. F., Calu, D. X., Cutting, A., Bidebsch, D. E., and Sayer, N. A. (2012). Prevalence and costs of co-occurring traumatic brain injury with and without outpatient disturbance and pain among Afghanistan and Iraq War Veteran VA. users Med. Care. 50, 342–346.

Temeljan, T., and Jaycon, L. H. (2008). Invisible Wounds of War: Psychological and Cognitive Injuries, their Consequences, and Services to Assist Recovery. Los Angeles: RAND Corporation, The RAND Centre for Military Health Policy Research. Thompson, J. M., Scott, K. C., and Dubinsky, L. (2008). Battlefield brain injury: unexplained symptoms and blast-related mild traumatic brain injury. Can. Fam. Physician 54, 1549–1551.

Townsend, W., Dibble, C., Abid, K., Vail, A., Sherwood, R., and Lecky, F. (2006). Rapid elimination of protein S-100B from serum after minor head trauma. J. Neurotrauma 23, 149–155.

Trudeau, D. L., Anderson, J., Hansen, L. M., Shagavel, D. N., Schmoller, J., Nugent, S., and Barton, S. (2008). Findings of mild traumatic brain injury in combat veterans with PTSD and a history of blast concus- sion. J. Neuropsychiatr. Clin. Neurosci. 20, 508–513.

Ursano, R. J., Silverman, M., Zhang, L., Carlton, J., Fullerton, C. S., Li, H., Johnson, L., and Benedek, D. (2010). Posttraumatic stress disorder and traumatic stress from bench to bedside, from war to disaster. Ann. N. Y. Acad. Sci. 1208, 72–81.

Vink, R., Nimmock, A. L., and Cernak, I. (2001). An overview of new and novel pharmacotherapies for use in traumatic brain injury. Clin. Exp. Pharmacol. Physiol. 28, 919–921.

Vitarbo, E. A., Chatzipanteli, K., Kinoshita, K., Truetter, J. S., Alonso, O. F., and Dietrich, W. D. (2004). Tumor necrosis factor alpha expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain tempera- ture. Neurosurgery 55, 416–424; discussion 424–415.

Vos, P. E., Jacobs, B., Andriessen, T. M., Lamers, K. J., Borm, G. F., Beens, T., Edwards, M., Rosmalen, C. F., and Vissers, J. L. (2010). GFAP and S100B are biomarkers of traumatic brain injury: an observa- tional cohort study. Neurology 75, 1786–1790.

Wallace, D. (2009). Improvised explosive devices and traumatic brain injury: the military experience in Iraq and Afghanistan. Australas. Psychiatry 17, 218–224.

Warden, D. L., Gordon, B., McCallister, T. W., Silver, J. M., Bardh, J. T., Bruns, J., Drake, A., Gentry, T., Jagoda, A., Katz, D. I., Kraus, J., Labbate, L. A., Ryan, L. M., Sparling, M. B., Walters, B., Whyte, J., Zapata, A., and Zitznay, G. (2006). Guidelines for the pharmacologic treatment of neurobehavioral sequelae of trau- matic brain injury. J. Neurotrauma 23, 1468–1501.

Wilk, J. E., Thomas, J. L., McGurk, D. M., Riviere, L., Castella, A., and Hoge, C. W. (2010). Mild traumatic brain injury (concussion) during combat: lack of association of blast mechanism with persistent postconcus- sive symptoms. J. Head Trauma Rehabil. 25, 9–14.

Woertgen, C., Rotheroe, R. D., Wies- mann, M., Misserl, U., and Brawan- ski, A. (2002). Glial and neuronal serum markers after controlled cortical impact injury in the rat. Acta Neurochir. (Wien) 144, 205–207.

Woicik, B. E., Stein, C. R., Bagg, K., Humphrey, R. I., and Orosco, J. (2010). Traumatic brain injury hos- pitalizations of U.S. army soldiers deployed to Afghanistan and Iraq. J. Am. Prev. Med. 38, S108–S116.

www.frontiersin.org
Wolf, S. J., Bebarta, V. S., Bonnett, C. J., Pons, P. T., and Cantrill, S. V. (2009). Blast injuries. Lancet 374, 405–415.

Young, A. B., Ott, L. G., Beard, D., Dempsey, R. J., Tibbs, P. A., and Mcclain, C. J. (1988). The acute-phase response of the brain-injured patient. J. Neurosurg. 69, 375–380.

Zemlan, F. P., Jauch, E. C., Mulchahrey, J. J., Gabbita, S. P., Rosenberg, W. S., Speciale, S. G., and Zuccarello, M. (2002). C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res. 947, 131–139.

Ziebell, J. M., and Morganti-Kossmann, M. C. (2010). Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 7, 22–30.

Zurek, J., Bartlova, L., and Fedora, M. (2012). The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury. Acta Neurochir. (Wien). 154, 93–103; discussion 103.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 26 March 2012; paper pending published: 15 April 2012; accepted: 12 June 2012; published online: 06 July 2012.

Citation: Agoston DV and Elsayed M (2012) Serum-based protein biomarkers in blast-induced traumatic brain injury spectrum disorder. Front. Neur. 3:107. doi: 10.3389/fneur.2012.00107

This article was submitted to Frontiers in Neurotrauma, a specialty of Frontiers in Neurology.

Copyright © 2012 Agoston and Elsayed. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.